FTC on ephedra
This article was originally published in The Tan Sheet
Executive Summary
FTC considers claims ephedra products are safe to be misleading and "we can and do go to federal court in order to stop" them, Bureau of Consumer Protection Director Howard Beales tells House Government Reform Committee March 27 during Internet pharmacy hearing. In response to question from Rep. Henry Waxman (D-Calif.), Beales states FTC has filed "four cases so far going back to 1997 challeng[ing] claims that ephedra was safe or had no side effects as unsubstantiated." He notes all four cases were decided in FTC's favor and that "we have other investigations involving ephedra products and there will be more cases that are in the pipeline"...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.